PMV Pharmaceuticals has appointed Philip Herman as Chief Commercial Officer to lead commercial strategy and launch preparation for rezatapopt, its first-in-class p53 reactivator, as the company plans to submit a New Drug Application for accelerated approval in platinum-resistant/refractory ovarian cancer in the first quarter of 2027. Herman brings over 24 years of experience in oncology and rare disease launches, having previously served as Chief Commercial and Portfolio Development Officer at Repare Therapeutics and CCO at Y-mAbs Therapeutics, where he led the launch of DANYELZA. PMV Pharma is completing enrollment in the PYNNACLE clinical trial and aims to bring the first therapy targeting mutant p53 to patients.
Pmv Pharmaceuticals IncPMV Pharma appoints a Chief Commercial Officer to prepare for the rezatapopt launch and planned NDA submission, a corporate/leadership development.
